Bicycle Therapeutics Files 8-K Report
Ticker: BCYC · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1761612
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: BCYC
TL;DR
BCYC filed an 8-K on 6/18/24 - check for updates.
AI Summary
On June 18, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and business operations. Specific details regarding new events or financial figures are not elaborated in the provided text, but the filing serves as an official record of these disclosures.
Why It Matters
This filing provides official updates from Bicycle Therapeutics plc to the SEC, which are crucial for investors and stakeholders to stay informed about the company's latest developments and financial standing.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain information that inherently increases risk.
Key Players & Entities
- Bicycle Therapeutics plc (company) — Registrant
- 001-38916 (company) — Commission File Number
- June 18, 2024 (date) — Date of Report
FAQ
What specific "Other Events" are being reported by Bicycle Therapeutics plc in this 8-K filing?
The provided text does not specify the details of the "Other Events" beyond listing the item information category.
What is the significance of the "Financial Statements and Exhibits" being filed?
This indicates that the company is providing updated financial information or relevant exhibits as required by the SEC, though the specifics are not detailed in the provided text.
When was Bicycle Therapeutics plc incorporated, and in which jurisdiction?
The filing states the company is incorporated in "England and Wales."
What is the Commission File Number for Bicycle Therapeutics plc?
The Commission File Number for Bicycle Therapeutics plc is 001-38916.
What is the Standard Industrial Classification (SIC) code for Bicycle Therapeutics plc?
The SIC code listed for Bicycle Therapeutics plc is 2834, which corresponds to "Pharmaceutical Preparations."
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-06-18 16:18:05
Filing Documents
- tm2417491d1_8k.htm (8-K) — 31KB
- tm2417491d1_ex5-1.htm (EX-5.1) — 110KB
- tm2417491_ex5-1img001.jpg (GRAPHIC) — 10KB
- 0001104659-24-072828.txt ( ) — 392KB
- bcyc-20240618.xsd (EX-101.SCH) — 3KB
- bcyc-20240618_def.xml (EX-101.DEF) — 26KB
- bcyc-20240618_lab.xml (EX-101.LAB) — 36KB
- bcyc-20240618_pre.xml (EX-101.PRE) — 25KB
- tm2417491d1_8k_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. On June 18, 2024, Bicycle Therapeutics plc (the " Company ") filed a prospectus supplement (the " Prospectus Supplement ") to its effective registration statement on Form S-3ASR (File No. 333-272248) (the " Registration Statement ") filed with the U.S. Securities and Exchange Commission, under the Securities Act of 1933, as amended, with respect to the resale by the selling securityholders named therein of up to 37,656,764 ordinary shares, nominal value 0.01 per share, of the Company (the " Shares "), with each ordinary share represented by one American Depositary Share. In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Cooley (UK) LLP, regarding the validity of the Shares being registered, which opinion is attached as Exhibit 5.1 to this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 5.1 Opinion of Cooley (UK) LLP. 23.1 Consent of Cooley (UK) LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 18, 2024 Bicycle Therapeutics plc By: /s/ Alethia Young Name: Alethia Young Title: Chief Financial Officer